NanoVibronix receives NHS Drug Tariff approval for UroShield actuators; contract extended to 4 years

ENvue Medical, Inc.

NHS Drug Tariff approval enables full reimbursement of UroShield actuators starting November 1, 2023 for clinicians to prescribe.
NHS Supply Chain contract extended up to four years via UK distribution partner Peak Medical Limited.
CEO Brian Murphy: reimbursement removes critical barrier; expects increased unit sales and production to meet demand.
UroShield is used for preventing Catheter-Associated Urinary Tract Infections (CAUTIs) in patients with indwelling catheters.
Patients can now receive full UroShield system with NHS covering cost, not patient.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.